The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global pen needles market reached a value of US$ XX Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Pen needles are disposable hollow needles used in pen injectors for delivering pharmaceutical drugs in the subcutaneous tissues of the body. The needle is fixed in the plastic hub of the medical injector pen and consists of plastic caps and individual wrapping for enhanced security and sterilization. Pen needles are manufactured using electro-polishing techniques to achieve smooth, fine and thin point tips for convenient penetration. They are available in a wide variety of gauge sizes and lengths and are majorly used by diabetic patients that require multiple dosages of insulin injections every day. In comparison to the traditionally used syringes and vials, pen needles are highly cost-effective, convenient to use, portable and do not require refrigeration.
The increasing prevalence of diabetes mellitus (DM) and other chronic medical disorders, such as osteoporosis, cardiovascular disease (CVD) and multiple sclerosis, is one of the key factors driving the growth of the market. The treatment of these ailments require multidrug regimen that involves daily or weekly administration of medicinal drugs with injector pens. Moreover, the rising geriatric population, which is more susceptible to chronic ailments is contributing to the growth of the market. Insulin pens provide a reliable, accurate and simplified dosing solution to the elderly patients and facilitate self-administration. Additionally, various product innovations, such as the development of ultra-thin and short-length needles with improved drug delivery systems, are acting as other growth-inducing factors. The traditionally used needles were difficult to use during self-dosage and caused more pain and discomfort to the patients. Other factors, including the increasing healthcare expenditure capacities of the masses, along with the implementation of favorable government policies promoting public health, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global pen needles market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on type, needle length, therapy, mode of purchase and end user.
Breakup by Type:
Breakup by Needle Length:
Breakup by Therapy:
Breakup by Mode of Purchase:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being A. Menarini Diagnostics srl, Advancare Pharma, Arkray Inc., B. Braun Melsungen AG, Becton Dickinson and Company, Hindustan Syringes & Medical Devices Ltd., HTL Strefa SA, Novo Nordisk A/S, Owen Mumford Ltd., Simple Diagnostics, Trividia Health Inc. (Sinocare) and Ultimed Inc.
|Base Year of the Analysis||2020|
|Segment Coverage||Type, Needle Length, Therapy, Mode of Purchase, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||A. Menarini Diagnostics srl, Advancare Pharma, Arkray Inc., B. Braun Melsungen AG, Becton Dickinson and Company, Hindustan Syringes & Medical Devices Ltd., HTL Strefa SA, Novo Nordisk A/S, Owen Mumford Ltd., Simple Diagnostics, Trividia Health Inc. (Sinocare) and Ultimed Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at